May 2nd 2024
Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.
Sandoz’ Edward Li on Using Filgrastim to Ease the Risk of Febrile Neutropenia
October 20th 2020Edward Li, PharmD, director of Health Economics and Outcomes Research for Sandoz, discussed how biosimilar filgrastim (Zarxio) used as primary prophylaxis saves money and helps reduce the risk of febrile neutropenia in patients with cancer.
Thomas Wakim On Neuclone’s Early Dive Into Developing PD-1 Inhibitor Biosimilars
October 15th 2020Thomas Wakim, strategic analyst for Neuclone, discussed the company’s decision to break into the world of PD-1 inhibitors, its partnership with the Serum Institute in India, and Neuclone’s biosimilar pipeline.
FTC's Markus H. Meier Talks About Restraint of Trade in the Biosimilar Marketplace
September 28th 2020Some acts by companies in the biologics marketplace may go too far in preventing free market activity, according to Markus H. Meier, acting director for the Federal Trade Commission (FTC) Bureau of Competition.
Stakeholders Joust Over Biosimilar Availability at PCOC20
September 25th 2020A diverse panel from practice, payer, and wholesale perspectives convened at The American Journal of Managed Care®'s Patient-Centered Oncology Care® 2020 virtual conference to hash out one of the hottest issues in biosimilar availability right now.